Does OLAPARIB Cause Prostatic specific antigen increased? 176 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 176 reports of Prostatic specific antigen increased have been filed in association with OLAPARIB (Lynparza). This represents 1.0% of all adverse event reports for OLAPARIB.
176
Reports of Prostatic specific antigen increased with OLAPARIB
1.0%
of all OLAPARIB reports
13
Deaths
13
Hospitalizations
How Dangerous Is Prostatic specific antigen increased From OLAPARIB?
Of the 176 reports, 13 (7.4%) resulted in death, 13 (7.4%) required hospitalization, and 4 (2.3%) were considered life-threatening.
Is Prostatic specific antigen increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 176 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Prostatic specific antigen increased?
ENZALUTAMIDE (3,731)
LEUPROLIDE (2,432)
ABIRATERONE (1,581)
RADIUM RA-223 DICHLORIDE (449)
RELUGOLIX (335)
BICALUTAMIDE (322)
DOCETAXEL (282)
APALUTAMIDE (251)
DENOSUMAB (220)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)
Which OLAPARIB Alternatives Have Lower Prostatic specific antigen increased Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL